In The News
Judge slashes contingency fee in Insurance Australia class action
ExxonMobil sues Andrew Forrest-linked NGO for defamation
Tenth junior doctors class action filed after run of court wins
Foxtel wins opposition to ‘originals IQ’ trade mark
BHP’s Mt Arthur Coal not permitted to conduct ‘trial by ambush’ in injury case
GM hit with class action over allegedly defective Holden transmissions
Another judge overturns decision for uncritical copying and pasting
Jetstar hits back at class action over COVID-19 flight credits
Exactech class action continues settlement talks despite US bankruptcy
Baker McKenzie partner returns from Hogan Lovells
Please login to bookmarkClose

The competition watchdog will not oppose Mylan NV’s proposed merger with Pfizer’s Upjohn Inc after the global pharmaceutical giants agreed to sell several off-patent brands to dispel competition concerns.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au